ZYNERBA PLC shares climbed 4.9% in early trading after the pharmaceuticals firm said it had completed a trial of its anti-inflammatory drug.The company said on Thursday that it had started a Phase 2 study on the drug in patients with Crohn’s disease, ulcerative colitis and ulcerable colitis.It said the drug could be available by the […]

Continue Reading...